<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080829</url>
  </required_header>
  <id_info>
    <org_study_id>HAL368</org_study_id>
    <nct_id>NCT05080829</nct_id>
  </id_info>
  <brief_title>Myeloid Mutations Register in R/R CML</brief_title>
  <official_title>ABL Mutation Register in Patients With ITK Relapsed or Refractory Chronic Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Cooperativo de Hemopatías Malignas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Cooperativo de Hemopatías Malignas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to know the percentage of ABL mutations in patients with chronic&#xD;
      myeloid leukemia that relapsed or are refractory to tyrosine-kinase inhibitors measured with&#xD;
      a myeloid mutations panel by NGS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of myeloid mutations by Next Generation Sequence</measure>
    <time_frame>1 year</time_frame>
    <description>Detection of positive myeloid mutations at detection of relapse or refractoriness to ITK treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Chronic Myeloid Leukaemia Recurrent</condition>
  <condition>Chronic Myeloid Leukemia, in Relapse</condition>
  <arm_group>
    <arm_group_label>Mutation Register</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure of myeloid mutations after detection of relapse or refractoriness to ITK treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Myeloid mutations measurement</intervention_name>
    <description>Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done</description>
    <arm_group_label>Mutation Register</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CML diagnosis by the WHO 2016 criteria&#xD;
&#xD;
          -  Failure to reach cytogenetic response of Ph chromosome of 36 to 95% at 3 months or&#xD;
             BCR/ABL &lt;10% at 6 months of treatment with TKI&#xD;
&#xD;
          -  Progression or relapse of the disease after previous response to treatment with TKI&#xD;
&#xD;
          -  Validation of adherence to treatment&#xD;
&#xD;
          -  Inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of information to complete the register&#xD;
&#xD;
          -  Failure to response achievement due lack of adherence to treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grupo Cooperativo de Hemopatías Malignas</name>
      <address>
        <city>Huixquilucan</city>
        <state>Estado De México</state>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Ovilla-Martinez, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>ovillarob@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pamela E Baez Islas, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>drabaez.hematologia@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

